razaxaban has been researched along with 1,2-di(5-amidino-2-benzofuranyl)ethane in 1 studies
Studies (razaxaban) | Trials (razaxaban) | Recent Studies (post-2010) (razaxaban) | Studies (1,2-di(5-amidino-2-benzofuranyl)ethane) | Trials (1,2-di(5-amidino-2-benzofuranyl)ethane) | Recent Studies (post-2010) (1,2-di(5-amidino-2-benzofuranyl)ethane) |
---|---|---|---|---|---|
20 | 0 | 2 | 7 | 0 | 0 |
Protein | Taxonomy | razaxaban (IC50) | 1,2-di(5-amidino-2-benzofuranyl)ethane (IC50) |
---|---|---|---|
Prothrombin | Homo sapiens (human) | 5 | |
Coagulation factor X | Homo sapiens (human) | 0.1 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheney, DL; Knabb, RM; Pinto, DJ; Smallheer, JM; Wexler, RR | 1 |
1 review(s) available for razaxaban and 1,2-di(5-amidino-2-benzofuranyl)ethane
Article | Year |
---|---|
Factor Xa inhibitors: next-generation antithrombotic agents.
Topics: Administration, Oral; Animals; Anticoagulants; Biological Availability; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Hemostasis; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Thrombosis | 2010 |